Nutritional immunology Nutritional, Metabolic, Endocrine
Conditions
Interventions
Participants were randomised using a web-based system managed by the Health Service Research Unit to receive daily oral supplementation with 400 IU vitamin D3 or placebo capsules for a period of 43 we
Sponsors
University of Aberdeen
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy individuals 2. Male or female 3. Aged 18 years or over 4. People taking = 200 IU/day vitamin D at screening but stopped taking the supplements during the study
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating 2. Receiving immunosuppressive or anti-inflammatory drug therapy 3. Taking vitamin D supplements (> 100 IU or 2.5 µg/day) 3. Immune-mediated disorders such as rheumatoid arthritis, multiple sclerosis, asthma, hay fever, lupus or eczema; kidney disease; cancer or other serious immune compromising conditions 4. Planned long-term (> 1 month) holidays abroad to sunny destinations
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of circulating Treg cells as a proportion of peripheral blood mononuclear cells (PBMCs) measured by flow cytometry following venous blood collection at baseline, weeks 4, 12, 25 and 43 | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured at baseline, weeks 4, 12, 25 and 43: 1. Serum 25(OH)D measured using tandem mass spectrometry as a response to vitamin D supplementation 2. Cytokine secretion (IL-10, and interferon-gamma) measured by ELISA 3. T cell proliferation in response to T cell stimulation measured by tritiated thymidine incorporation | — |
Countries
United Kingdom
Contacts
Public ContactWakunyambo Maboshe
Outcome results
None listed